Table 1 (abstract P462). Patients’ clinical and laboratory features
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Pt (age in yrs) | Pt. 1 (14) | Pt. 2 (15) | Pt. 3 (11) | Pt. 4 (17) | Pt. 5 (9) | Pt. 6 (10) | Pt. 7 (20) | Pt. 8 (9) | Pt. 9 (18) |
|---|---|---|---|---|---|---|---|---|---|
Age at sJIA onset (yrs) | 13 | 6 | 6 | 13 | 4 | 10 | 2 | 4 | 7 |
History of MAS | Yes | No | No | Yes | Yes | No | Yes | Yes | Yes |
Treatment at time of infection (dose) | Anakinra (2 mg/Kg/day) | Canakinumab (4 mg/kg every 7 weeks) | Canakinumab (7 mg/kg every 4 weeks) Prednisone (0,1 mg/kg/day) | Anakinra (2 mg/kg/day) | Canakinumab (5 mg/kg every 4 weeks) | Anakinra (2 mg/kg/day) | Anakinra (3 mg/kg/day Prednisone (0,2 mg/kg/day) | Anakinra (4 mg/kg/day) | Canakinumab (3 mg/kg every 12 weeks) |
Comorbidity | No | No | cardiopathy | epilepsy, polineuropathy | No | No | No | No | epilepsy |
SARS-COV2 infection | |||||||||
 Symptoms | Rhinitis | Fever, ageusia, anosmia, arthralgia, vomiting | Headache | Rhinitis | Fever, rhinitis | Fever, myalgia | Fever, rhinitis, pharyngodynia | Rhinitis | Fever |
 Laboratory analysis | Not done | In the normal range | Not done | ↑ CRP | ↓ PLTs, ↓ WBC | Not done | Not done | Not done | Not done |
 Hospitalization | No | Yes | No | No | Yes | No | No | No | No |
 Additional treatments (dose) | Azithromycin Increased dose of Anakinra (3,5 mg/kg/day) | Anakinra (2 mg/kg/day) | No | No | No | Increased dose of Anakinra (4 mg/kg/day) | No | No | Increase dose of Canakinumab (3 mg/kg every 4 weeks) |